Ginkgo Bioworks IPO
Ginkgo Bioworks is a synthetic biology company that uses engineered microorganisms to produce chemicals, materials, and other products. Investors are interested in the company's platform approach to biotechnology and its potential to revolutionize manufacturing across multiple industries.
Key Facts
| Industry | Synthetic Biology |
| Founded | 2009 |
| Headquarters | Boston, MA |
| Employees | ~1,200 |
| Website | ginkgobioworks.com |
| Funding | SPAC merger with Soaring Eagle Acquisition Corp at $2.5B valuation in 2021. Total raised: ~$2.5B |
About Ginkgo Bioworks
Ginkgo Bioworks operates as the 'Amazon Web Services for biology,' providing automated organism engineering services to companies across pharmaceuticals, agriculture, industrial chemicals, and consumer products. The company's platform combines robotics, software, and biology expertise to design and manufacture custom microorganisms for clients, essentially programming cells like software code. Ginkgo's foundries can run thousands of experiments simultaneously, dramatically reducing the time and cost of biological R&D.
The company went public via SPAC in 2021 and has since expanded into biosecurity and pandemic preparedness through its Concentric platform, which provides pathogen monitoring and detection services. Ginkgo has faced scrutiny over its revenue recognition practices and high cash burn rate, but continues to build strategic partnerships with major corporations like Bayer and Roche while expanding its cell programming capabilities across new therapeutic areas.
IPO Status
Ginkgo Bioworks went public in September 2021 through a SPAC merger with Soaring Eagle Acquisition Corp, valuing the company at approximately $2.5 billion. The stock began trading on the NYSE under the ticker symbol 'DNA'. Since going public, the company's stock performance has been volatile, reflecting broader market sentiment toward growth-stage biotech companies and SPACs. Ginkgo continues to expand its synthetic biology platform and partnerships across various industries including pharmaceuticals, agriculture, and industrial biotechnology.
Competitors
Frequently Asked Questions
Does Ginkgo Bioworks have a stock?
Yes, Ginkgo Bioworks completed its IPO in September 2021 through a SPAC merger. The company now trades publicly on the NYSE under the ticker symbol 'DNA'.
When is the Ginkgo Bioworks IPO date?
Ginkgo Bioworks already went public in September 2021, so there is no upcoming IPO date. The company completed its public listing through a SPAC transaction.
How can I buy Ginkgo Bioworks stock?
You can buy Ginkgo Bioworks stock through any major brokerage since it trades publicly on the NYSE under ticker 'DNA'. The stock is available for purchase during regular market hours through traditional investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts